View in EDS HTML Full Text PDF Full Text

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial.

Saved in:
Bibliographic Details
Title: Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial.
Authors: Magnolo, Nina1 (AUTHOR) nina.magnolo@ukmuenster.de, Soung, Jennifer2,3 (AUTHOR), Frew, John4,5,6 (AUTHOR), Costanzo, Antonio7,8 (AUTHOR), Ruiz-Santiago, Hiram9 (AUTHOR), Eyerich, Kilian10 (AUTHOR), Llamas-Velasco, Mar11 (AUTHOR), Bukhalo, Michael12 (AUTHOR), Sivamani, Raja K.13 (AUTHOR), Moore, Angela14,15,16 (AUTHOR), Wu, Tianshuang17 (AUTHOR), Xie, Jiaheng17 (AUTHOR), Patel, Manish17 (AUTHOR), Ashley, Doug17 (AUTHOR), Kaplan, Blair17 (AUTHOR), Stakias, Vassilis17 (AUTHOR), Espaillat, Ramon17 (AUTHOR), Warren, Richard B.18 (AUTHOR)
Source: Dermatology & Therapy. Jul2026, Vol. 16 Issue 7, p3415-3429. 15p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:21938210
DOI:10.1007/s13555-026-01779-x